Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ho

Showing results (1301-1310 of 1,367) with videos related to

Pageof 137
Sort By:
Elife|November 16, 2022
Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort studyJames A Hay, Stephen M Kissler, Joseph R Fauver, et al.
Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.
Plos One|January 30, 2010
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccineSandhya Vasan, Sarah J Schlesinger, Zhiwei Chen, et al.
Leukemia|February 25, 2017
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoA Chaturvedi, L Herbst, S Pusch, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2001
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoJ M Strizki, S Xu, N E Wagner, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2020
Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding DomainsTongqing Zhou, Yaroslav Tsybovsky, Adam S Olia, et al.
Research Square|August 26, 2020
Modeling COVID-19 with Human Pluripotent Stem Cell-Derived Cells Reveals Synergistic Effects of Anti-inflammatory Macrophages with ACE2 Inhibition Against SARS-CoV-2Fuyu Duan, Liyan Guo, Liuliu Yang, et al.
Blood|June 23, 2018
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associationsAndrea Pellagatti, Richard N Armstrong, Violetta Steeples, et al.
Blood|June 13, 2015
Recurrent CDKN1B (p27) mutations in hairy cell leukemiaSascha Dietrich, Jennifer Hüllein, Stanley Chun-Wei Lee, et al.
Pageof 137

Showing results (1301-1310 of 1,367) with videos related to

Sort By:
Pageof 137
Elife|November 16, 2022
Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort studyJames A Hay, Stephen M Kissler, Joseph R Fauver, et al.
Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.
Plos One|January 30, 2010
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccineSandhya Vasan, Sarah J Schlesinger, Zhiwei Chen, et al.
Leukemia|February 25, 2017
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoA Chaturvedi, L Herbst, S Pusch, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2001
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoJ M Strizki, S Xu, N E Wagner, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2020
Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding DomainsTongqing Zhou, Yaroslav Tsybovsky, Adam S Olia, et al.
Research Square|August 26, 2020
Modeling COVID-19 with Human Pluripotent Stem Cell-Derived Cells Reveals Synergistic Effects of Anti-inflammatory Macrophages with ACE2 Inhibition Against SARS-CoV-2Fuyu Duan, Liyan Guo, Liuliu Yang, et al.
Blood|June 23, 2018
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associationsAndrea Pellagatti, Richard N Armstrong, Violetta Steeples, et al.
Blood|June 13, 2015
Recurrent CDKN1B (p27) mutations in hairy cell leukemiaSascha Dietrich, Jennifer Hüllein, Stanley Chun-Wei Lee, et al.
Pageof 137